Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20090148531 A1
Publication typeApplication
Application numberUS 12/368,884
Publication dateJun 11, 2009
Filing dateFeb 10, 2009
Priority dateSep 24, 1999
Also published asCA2387536A1, CA2387536C, CN1376148A, DE19945982A1, DE60005031D1, DE60005031T2, EP1214300A2, EP1214300B1, US9028876, US20120172364, WO2001023362A2, WO2001023362A3
Publication number12368884, 368884, US 2009/0148531 A1, US 2009/148531 A1, US 20090148531 A1, US 20090148531A1, US 2009148531 A1, US 2009148531A1, US-A1-20090148531, US-A1-2009148531, US2009/0148531A1, US2009/148531A1, US20090148531 A1, US20090148531A1, US2009148531 A1, US2009148531A1
InventorsThomas Hantke, Bettina Rehbock, Joerg Rosenberg, Joerg Breitenbach
Original AssigneeThomas Hantke, Bettina Rehbock, Joerg Rosenberg, Joerg Breitenbach
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Rate-controlled particles
US 20090148531 A1
Abstract
Rate-controlled particles, comprising compounds of the formula
as a solid dispersion.
Images(9)
Previous page
Next page
Claims(16)
1. (canceled)
2. Particles according to claim 16, wherein the copolymer of N-vinylpyrrolidone is a copolymer with vinyl acetate.
3. Particles according to claim 16, further comprising a surfactant.
4. Particles according to claim 3, wherein the surfactant is a PEG-n-hydrogenated castor oil.
5. Particles according to claim 16, wherein the surfactant is a low molecular weight poly-oxyethylene polyoxypropylene block copolymer.
6. Particles according to claim 16, further comprising citric acid in amounts of up to 5% b.w.
7. Particles according to claim 16, wherein the home- or copolymer of N-vinylpyrrolidone is used in amounts of from 40 to 70% b.w. of the total weight of the dosage form.
8. Particles according to claim 7, wherein the homo- or copolymer of N-vinylpyrrolidone is used in amounts of from 50 to 65% b.w.
9. Particles according to claim 16, wherein the controlled release is an instant release of the drug.
10. Particles according to a claim 16, wherein the controlled release is a sustained release.
11. Particles according to claim 10, further comprising hydroxypropyl methyl cellulose in amounts of from 5 to 10% b.w.
12. Particles according to claim 16, obtained by forming a homogeneous mixture of the components in the form of a melt, extruding said mixture and shaping of the extrudate.
13. Particles according to claim 16, comprising a compound selected from the group consisting of
4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidin]amino]-benzonitrile;
4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]amino]benzonitrile;
4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile;
a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
14. Pharmaceutical dosage form, comprising particles according to claim 16.
15. Pharmaceutical dosage forms according to claim 14, further comprising one or more pharmaceutically acceptable excipients
16. Rate-controlled release particles, comprising a compound of formula II
an N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein
-b1=b2-C(R2a)=b3-b4=represents a bivalent radical of formula

—CH═CH—C(R2a)═CH—CH═  (b-1);

—N═CH—C(R2a)═CH—CH═  (b-2);

—CH═N—C(R2a)═CH—CH═  (b-3);

—N═CH—C(R2a)═N—CH═  (b-4);

—N═CH—C(R2a)═CH—N═  (b-5);

—CH═N-c(R2a)═N—CH═  (b-6);

—N═N—C(R2a)═CH—CH═  (b-7);
q is 0, 1, 2; or where possible q is 3 or 4;
R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl;
R2a is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C1-6alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, C2-6alkenyl substituted with cyano, or C2-6alkynyl substituted with cyano;
each R2 independently is hydroxy, halo, C1-6alkyl optionally substituted with cyano or —C(═O)R6, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms or cyano, C2-6alkynyl optionally substituted with one or more halogen atoms or cyano, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)R6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a radical of formula
wherein each A independently is N, CH or CR6;
B is NH, O, S or NR6;
p is 1 or 2; and
R6 is methyl, amino, mono- or dimethylamino or polyhalomethyl;
L is C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-7cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from
C3-7cycloalkyl,
indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C1-6alkyl, hydroxy, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C1-6alkylcarbonyl,
phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R2; or
L is —X—R3 wherein
R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R2; and
X is —NH—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—;
Q represents hydrogen, C1-6alkyl, halo, polyhaloC1-6alkyl or —NR4R5; and
R4 and R5 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-2alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-2alkyl)aminocarbonyl
wherein each of the aforementioned C1-2alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C1-6alkyloxy, hydroxyc1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, cyano, amino, imino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(O)R6, —C(═NH)R6, aryl and Het; or
R4 and R5 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-2alkyl)aminoC1-4-alkylidene;
Y represents hydroxy, halo, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms, C2-6alkynyl optionally substituted with one or more halogen atoms, C1-6alkyl substituted with cyano or —C(═O)R6, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(NH)R6 or aryl;
aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy;
Het is an aliphatic or aromatic heterocyclic radical;
said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl-, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy,
as a solid dispersion in a polymeric matrix, wherein the polymeric matrix is consisting of a homo- or copolymer of N-vinylpyrrolidone.
Description
  • [0001]
    The present invention concerns pharmaceutical compositions in the form of rate-controlled particles, comprising compounds of the formula (I) to (VI)
  • [0002]
    (I) is an antiviral compound of formula
  • [0000]
  • [0000]
    a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof, wherein
    • Y is CR5 or N;
    • A is CH, CR4 or N;
    • n is 0, 1, 2, 3 or 4;
    • Q is —NR1R2 or when Y is CR5 then Q may also be hydrogen;
    • R1 and R2 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)-amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C1-6alkyloxy, hydroxy-C1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, cyano, amino, imino, aminocarbonyl, aminocarbonylamino, mono- or di(C1-6alkyl)amino, aryl and Het; or
    • R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4-alkylidene;
    • R3 is hydrogen, aryl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxy-carbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; and
    • each R4 independently is hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalo-methyloxy, or when Y is CR5 then R4 may also represent C1-6alkyl substituted with cyano or aminocarbonyl;
    • R5 is hydrogen or C1-4alkyl;
    • L is —X1—R6 or —X2-Alk-R7 wherein
      • R6 and R7 each independently are phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl; or when Y is CR5 then R6 and R7 may also be selected from phenyl substituted with one, two, three, four or five substituents each independently selected from aminocarbonyl, trihalomethyloxy and trihalomethyl; or when Y is N then R6 and R7 may also be selected from indanyl or indolyl, each of said indanyl or indolyl may be substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C1-6alkyl, C1-6alkyloxy, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, formyl, cyano, nitro, amino, and trifluoromethyl;
      • X1 and X2 are each independently —NR3—, —NH—NH—, —N═N—, —O—, —S—, —S(═O)— or —S(═O)2—;
      • Alk is C1-4alkanediyl; or
    • when Y is CR5 then L may also be selected from C1-10alkyl, C3-10alkenyl, C3-10alkynyl, C3-7cycloalkyl, or C1-10alkyl substituted with one or two substituents independently selected from C3-7cycloalkyl, indanyl, indolyl and phenyl, wherein said phenyl, indanyl and indolyl may be substituted with one, two, three, four or where possible five substituents each independently selected from halo, hydroxy, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, C1-6alkyloxy-carbonyl, formyl, nitro, amino, trihalomethyl, trihalomethyloxy and C1-6alkylcarbonyl;
    • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy, cyano, nitro and trifluoromethyl;
    • Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.
  • [0019]
    The compounds of formula (I) can be prepared according to the methods described in the patent applications with application number PCT/EP99/02043 and PCT/EP99/02044.
  • [0020]
    (II) is an antiviral compound of formula
  • [0000]
  • [0000]
    the N-oxides, the pharmaceutically acceptable addition salts, quaternary amines and the stereochemically isomeric forms thereof, wherein
    • -b1=b2-C(R2a)=b3-b4=represents a bivalent radical of formula
  • [0000]

    —CH═CH—C(R2a)═CH—CH═  (b-1);
  • [0000]

    —N═CH—C(R2a)═CH—CH═  (b-2);
  • [0000]

    —CH═N—C(R2a)═CH—CH═  (b-3);
  • [0000]

    —N═CH—C(R2a)═N—CH═  (b-4);
  • [0000]

    —N═CH—C(R2a)═CH—N═  (b-5);
  • [0000]

    —CH═N—C(R2a)═N—CH═  (b-6);
  • [0000]

    —N═N—C(R2a)═CH—CH═  (b-7);
    • q is 0, 1, 2; or where possible q is 3 or 4;
    • R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl;
    • R2a is cyano, aminocarbonyl, mono- or di(methyl)aminocarbonyl, C1-6alkyl substituted with cyano, aminocarbonyl or mono- or di(methyl)aminocarbonyl, C2-6alkenyl substituted with cyano, or C2-6alkynyl substituted with cyano;
    • each R2 independently is hydroxy, halo, C1-6alkyl optionally substituted with cyano or —C(═O)R6, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms or cyano, C2-6alkynyl optionally substituted with one or more halogen atoms or cyano, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6 or a radical of formula
  • [0000]
  • [0000]
    wherein each A independently is N, CH or CR6;
      • B is NH, O, S or NR6;
      • p is 1 or 2; and
      • R6 is methyl, amino, mono- or dimethylamino or polyhalomethyl;
    • L is C1-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-7cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from
      • C3-7cycloalkyl,
      • indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C1-6alkyl, hydroxy, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C1-6alkylcarbonyl,
      • phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R2; or
    • L is —X—R3 wherein
      • R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R2; and
      • X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—;
    • Q represents hydrogen, C1-6alkyl, halo, polyhaloC1-6alkyl or —NR4R5; and
    • R4 and R5 are each independently selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-22alkyloxycarbonyl, aryl, amino, mono- or di(C1-12alkyl)amino, mono- or di(C1-12alkyl)aminocarbonyl wherein each of the aforementioned C1-12alkyl groups may optionally and each individually be substituted with one or two substituents each independently selected from hydroxy, C1-6alkyloxy, hydroxyC1-6alkyloxy, carboxyl, C1-6alkyloxycarbonyl, cyano, amino, imino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R6, —C(═NH)R6, aryl and Het; or
    • R4 and R5 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-12alkyl)aminoC1-4alkylidene;
    • Y represents hydroxy, halo, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms, C2-6alkynyl optionally substituted with one or more halogen atoms, C1-6alkyl substituted with cyano or —C(═O)R6, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR6, —NH—S(═O)pR6, —C(═O)R6, —NHC(═O)H, —C(═O)NHNH2, NHC(═O)R6, —C(═NH)R6 or aryl;
    • aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy;
    • Het is an aliphatic or aromatic heterocyclic radical; said aliphatic heterocyclic radical is selected from pyrrolidinyl, piperidinyl, homopiperidinyl, piperazinyl, morpholinyl, tetrahydrofuranyl and tetrahydrothienyl wherein each of said aliphatic heterocyclic radical may optionally be substituted with an oxo group; and said aromatic heterocyclic radical is selected from pyrrolyl, furanyl, thienyl, pyridinyl, pyrimidinyl, pyrazinyl and pyridazinyl wherein each of said aromatic heterocyclic radical may optionally be substituted with hydroxy.
  • [0042]
    The compounds of formula (II) can be prepared according to the methods described in the U.S. patent applications with application No. 60/143,962 and 60/107,792.
  • [0043]
    (III) is an antiviral compound of formula
  • [0000]
  • [0000]
    a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine or a stereochemically isomeric form thereof, wherein -a1=a2-a3=a4- represents a bivalent radical of formula
  • [0000]

    —CH═CH—CH═CH—  (a-1);
  • [0000]

    —N═CH—CH═CH—  (a-2);
  • [0000]

    —N═CH—N═CH—  (a-3);
  • [0000]

    —N═CH—CH═N—  (a-4);
  • [0000]

    —N═N—CH═CH—  (a-5);
    • n is 0, 1, 2, 3 or 4; and in case -a1=a2-a3-a4- is (a-1), then n may also be 5;
    • R1 is hydrogen, aryl, formyl, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with formyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl; and
    • each R2 independently is hydroxy, halo, C1-6alkyl optionally substituted with cyano or —C(═O)R4, C3-7cycloalkyl, C2-6alkenyl optionally substituted with one or more halogen atoms or cyano, C2-6alkynyl optionally substituted with one or more halogen atoms or cyano, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, —S(═O)pR4, —NH—S(═O)pR4, —C(═O)R4, —NHC(═O)H, —C(═O)NHNH2, —NHC(═O)R4, —C(═NH)R4 or a radical of formula
  • [0000]
  • [0000]
    wherein each A independently is N, CH or CR4;
      • B is NH, O, S or NR4;
      • p is 1 or 2; and
      • R4 is methyl, amino, mono- or dimethylamino or polyhalomethyl;
    • L is C4-10alkyl, C2-10alkenyl, C2-10alkynyl, C3-7cycloalkyl, whereby each of said aliphatic group may be substituted with one or two substituents independently selected from
      • C3-7cycloalkyl,
      • indolyl or isoindolyl, each optionally substituted with one, two, three or four substituents each independently selected from halo, C1-6alkyl, hydroxy, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, polyhalomethyl, polyhalomethyloxy and C1-6alkylcarbonyl,
      • phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with one, two, three, four or five substituents each independently selected from the substituents defined in R2; or
    • L is —X—R3 wherein
      • R3 is phenyl, pyridinyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein each of said aromatic rings may optionally be substituted with two, three, four or five substituents each independently selected from the substituents defined in R2; and
      • X is —NR1—, —NH—NH—, —N═N—, —O—, —C(═O)—, —CHOH—, —S—, —S(═O)— or —S(═O)2—; aryl is phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl and polyhaloC1-6alkyloxy.
  • [0057]
    The compounds of formula (III) can be prepared according to the methods described in the U.S. patent application with application No. 60/107,799.
  • [0058]
    (IV) is an antiviral compound of formula
  • [0000]
  • [0000]
    the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein
    • R1 and R2 are each independently selected from hydrogen; hydroxy; amino; C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyl-oxycarbonyl; Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)aminocarbonyl; dihydro-2(3H)-furanone; C1-6alkyl substituted with one or two substituents each independently selected from amino, imino, aminocarbonyl, aminocarbonyl-amino, hydroxy, hydroxyC1-6alkyloxy, carboxyl, mono- or di(C1-6alkyl)amino, C1-6alkyloxycarbonyl and thienyl; or
    • R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)aminoC1-4-alkylidene;
    • R3 is hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; and
    • R4, R5, R6, R7 and R8 are each independently selected from hydrogen, hydroxy, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy
    • L is C1-10alkyl; C3-10alkenyl; C3-10alkynyl; C3-7cycloalkyl; or
    • L is C1-10alkyl substituted with one or two substituents independently selected from C3-7cycloalkyl; indolyl or indolyl substituted with one, two, three or four substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C1-6alkylcarbonyl; phenyl or phenyl substituted with one, two, three, four or five substituents each independently selected from halo, hydroxy, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl, trihalomethyloxy, C1-6alkylcarbonyl; and,
  • [0065]
    Ar1 is phenyl, or phenyl substituted with one, two or three substituents each independently selected from halo, C1-6alkyl, C1-6alkyloxy, cyano, nitro or trifluoromethyl; with the proviso that compounds (a) to (o)
  • [0000]
    Co.
    No. Alk R1/R2 R3 R4 R5 R6 R7 R8
    a 1-(4-(2-methylpropyl)phenyl)ethyl H/H H CH3 H H H H
    b 1-(4-(2-methylpropyl)phenyl)ethyl H/H H H H NO2 H H
    c 1-(4-(2-methylpropyl)phenyl)ethyl H/H C6H5 H H H H H
    d 1-(4-(2-methylpropyl)phenyl)ethyl H/H H NO2 H CH3 H H
    e 1-(4-(2-methylpropyl)phenyl)ethyl H/H H H H NH2 H H
    f 4-(2-methylpropyl)phenylmethyl H/H H H CF3 H H H
    g 1-(4-(2-methylpropyl)phenyl)ethyl H/H H H H Cl H H
    h 4-(2-methylpropyl)phenylmethyl H/H H H H H H H
    i 3,4-dimethoxyphenylmethyl H/H H H H H H H
    j 2,3-dimethoxyphenylmethyl H/H H H H H H H
    k 3,4-diethoxyphenylmethyl H/H H H H H H H
    l 2-(3,5-(1,1-dimethylethyl)-4- H/H H H H H H H
    hydroxy-phenyl)ethyl
    m 2-(3,5-(1,1-dimethylethyl)-4- H/H H H t-Bu OH t-Bu H
    hydroxy-phenyl)ethyl
    n Phenylmethyl H/H H CH3 H H H H
    o Phenylmethyl H/H H H H H H H

    are not included.
  • [0066]
    The compounds of formula (IV) can be prepared according to the methods described in EP-A-0834507.
  • [0067]
    (V) is an antifungal compound of formula
  • [0000]
  • [0000]
    the N-oxide forms, the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, wherein
    • n is zero, 1, 2 or 3;
    • X is N or CH;
    • each R1 independently is halo, nitro, cyano, amino, hydroxy, C1-4alkyl, C1-4alkyloxy or trifluoromethyl;
    • R2 is hydrogen; C3-7alkenyl; C3-7alkynyl, aryl; C3-7cycloalkyl; C1-6alkyl or C1-6alkyl substituted with hydroxy, C1-4alkyloxy, C3-7cycloalkyl or aryl;
    • R3 and R4 each independently are hydrogen, C1-6alkyl, C3-7cycloalkyl or aryl; or
    • R3 and R4 taken together form a bivalent radical —R3-R4— of formula:
  • [0000]
      • wherein R5a, R5b, R5c, R5d each independently are hydrogen, C1-6alkyl or aryl; and
        aryl is phenyl or phenyl substituted with one, two or three substituents selected from halo, nitro, cyano, amino, hydroxy, C1-4alkyl, C1-4alkyloxy or trifluoromethyl.
  • [0075]
    The compounds of formula (V) can be prepared according to the methods described in WO 99/02523.
  • [0076]
    (VI) is an apolipoprotein-B synthesis inhibitor of formula
  • [0000]
  • [0000]
    the N-oxides, the stereochemically isomeric forms thereof, and the pharmaceutically acceptable acid addition salts, wherein A and B taken together form a bivalent radical of formula
  • [0000]

    —N═CH—  (a),
  • [0000]

    —CH═N—  (b),
  • [0000]

    —CH2—CH2—  (c),
  • [0000]

    —CH═CH—  (d),
  • [0000]

    —C(═O)—CH2—  (e),
  • [0000]

    —CH2—C(═O)—  (f),
  • [0000]
    in the bivalent radicals of formula (a) and (b) the hydrogen atom may be replaced by C1-6alkyl; in the bivalent radicals of formula (c), (d), (e), (f), one or two hydrogen atoms may be replaced by C1-6alkyl;
    • R1 is hydrogen, C1-6alkyl or halo;
    • R2 is hydrogen or halo;
    • R3 is hydrogen; C1-8alkyl; C3-6cycloalkyl; or C1-8alkyl substituted with hydroxy, oxo, C3-6cycloalkyl or aryl;
    • Het is a heterocycle selected from the group consisting of pyridine; pyridine substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)amino or aryl; pyrimidine; pyrimidine substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)-amino or aryl; tetrazole; tetrazole substituted with C1-6alkyl or aryl; triazole; triazole substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)-amino; thiadiazole; thiadiazole substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)-amino; oxadiazole substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)amino; imidazole; imidazole substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)amino; thiazole; thiazole substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)amino; oxazole; oxazole substituted with one or two substituents selected from C1-6alkyl, hydroxy, C1-6alkyloxy, trihalomethyl, amino, mono- or di(C1-6alkyl)amino;
    • aryl is phenyl or phenyl substituted with C1-6alkyl or halo.
  • [0082]
    The heterocyclic radical “Het” is bound to the sulfur atom via a carbon atom.
  • [0083]
    The compounds of formula (VI) can be prepared according to the methods described in WO 96/13499.
  • [0084]
    The particles comprise the compounds of formula (I) to (VI) as a solid dispersion in a polymeric matrix, wherein the polymeric matrix is consisting of a homo- or copolymer of N-vinyl-pyrrolidone. Furthermore, the invention concerns a process for manufacturing of such particles and pharmaceutical dosage forms comprising such particles.
  • [0085]
    The compounds of formula (I) to (VI) contained in the particles show poor bio-availability.
  • [0086]
    In order to improve the dissolution characteristics the compounds are dispersed in a polymeric matrix, preferably by using a melt-extrusion process.
  • [0087]
    EP-A 0 240 904 discloses a method for producing solid pharmaceutical forms by extrusion of polymer melts which contain active substances, using as polymers homo- or copolymers of N-vinyl-pyrrolidone.
  • [0088]
    EP-B 0 580 860 discloses a method for producing solid dispersions of drug substances in a polymeric matrix using a twin screw extruder.
  • [0089]
    It is an object of the present invention to provide rate-controlled pharmaceutical forms containing the aforementioned compounds.
  • [0090]
    We have found that this object is achieved by the particles defined at the outset.
  • [0091]
    Preferred compounds according to the invention are:
    • 4-[[4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]benzo nitrile;
    • 4-[[2-[(cyanophenyl)amino]-4-pyrimidinyl]amino]-3,5-dimethyl-benzonitrile;
    • 4-[[4-amino-5-chloro-6-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
    • 4-[[5-chloro-4-[(2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
    • 4-[[5-bromo-4-(4-cyano-2,6-dimethylphenoxy)-2-pyrimidinyl]-amino]benzonitrile;
    • 4-[[4-amino-5-chloro-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]amino]benzonitrile;
    • 4-[[5-bromo-6-[(4-cyano-2,6-dimethylphenyl)amino]-2-pyrimidinyl]-amino]benzonitrile;
    • 4-[[4-amino-5-chloro-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile;
    • 4-[[4-amino-5-bromo-6-(4-cyano-2,6-dimethylphenyloxy)-2-pyrimidinyl]amino]benzonitrile;
    • 4-[[4-[(2,4,6-trimethylphenyl)amino]-1,3,5-triazin-2-yl]amino]-benzonitrile;
    • 4-[[4-amino-6-[(2,6-dichlorophenyl)methyl]-1,3,5-triazin-2-yl]-amino]benzonitrile;
    • 4-[[4-[(2,6-dichlorophenyl)methyl]-6-(hydroxyamino)-1,3,5-triazin-2-yl]amino]benzonitrile;
    • 1-[4-[4-[4-[[4-(2,4-difluorophenyl)-4-(1H-1,2,4-triazol-1-yl-methyl)-1,3-dioxolan-2-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-3-(1-methylethyl)-2-imidazolidinone;
    • (−)-[2S-[2alpha,4alpha(S*)]]-4-[4-[4-[4-[[2-(4-chlorophenyl)-2-[[(4-methyl-4H-1,2,4-triazol-3-yl)thio]methyl]-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]-2,4-dihydro-2-(1-methyl-propyl)-3H-1,2,4-triazol-3-one,
      a N-oxide, a pharmaceutically acceptable addition salt or a stereochemically isomeric form thereof.
  • [0106]
    According to the present invention the term “rate-controlled” means that depending on the composition of the matrix the particles can show instant release of the active ingredient or modified release (sustained release).
  • [0107]
    The compounds according to the invention are homogeneously dispersed in a polymer matrix consisting of a homopolymer of N-vinylpyrrolidone or, preferably, a copolymer of N-vinyl-pyrrolidone. A preferred copolymer is a copolymer of N-vinyl-pyrrolidone and vinyl acetate, especially a copolymer obtained from 60% b.w. of NVP and 40% b.w. of vinylacetate.
  • [0108]
    The polymers show Fikentscher K values of from 17 to 90, preferably a K value of 30 (for the definition of the K value see “H. Fikentscher, Cellulose-Chemie” (1932), 58-64 and 71-74).
  • [0109]
    The polymeric matrix component is used in amounts of from 40 to 70, preferably of from 50 to 65% b.w. of the total weight of the particles.
  • [0110]
    In a preferred embodiment of the invention the polymeric matrix further comprises a surfactant, preferably a surfactant with a HLB-value of 10-18 (HLB: Hydrophilic Lipophilic Balance). Especially preferred surfactants are selected form the group consisting of low molecular weight polyoxyethylene polyoxy-propylene block copolymers with a mean molecular weight of 1000 to 6000 g/mol, and hydrogenated castor oil which can be modified with polyethylene glycol.
  • [0111]
    The amounts of surfactants used lies in the range of up to 20% b.w., preferably 5 to 15% b.w., of the particles.
  • [0112]
    In another preferred embodiment the matrix further comprises an organic carboxylic acid in amounts of up to 5% b.w. of the particles.
  • [0113]
    In another preferred embodiment of the invention the polymeric matrix further comprises hydroxypropyl methyl cellulose in amounts of up to 25% b.w., preferably from 5 to 10% b.w.
  • [0114]
    The particles of the present invention are prepared as solid dispersions of the active compounds in a polymeric matrix. The term “solid dispersion” is well known in the art and means a dispersion consisting of solid components. Preferably solid dispersions are in the form of solid solutions wherein the active ingredients are molecularly dispersed in the polymeric matrix.
  • [0115]
    Such solid dispersion is preferably obtained by forming a homogeneous mixture of the components in the form of a melt, extruding said melt and shaping of the extrudate. The melting is effected by the input of thermal and/or mechanic energy.
  • [0116]
    Depending on the composition of the matrix, the melting takes place in the range of from 40 C. to 190 C., preferably 50 to 150 C. The suitable temperature range depends on the glass transition temperature of the polymer component, the properties of the active ingredients and further additives. The optimal temperature range can be established by a few simple tests.
  • [0117]
    The mixing of the active substances with the polymer and additional components of the matrix can take place before or after the melting of the polymer. Preferably the process is solvent-free which means that no additional organic solvents or water are added.
  • [0118]
    The plastification and melting preferably can take place in an extruder, a kneader or a mixing reactor, preferably in an extruder having one or more screws which may rotate in the same direction or opposite directions, especially in a twin screw extruder. The latter can be operated with or without kneading elements, but use of kneading elements is preferred because mixing is better.
  • [0119]
    The still plastic material is extruded through a die or a breaker plate and then shaped into particles. This may be effected by milling and subsequent sieving the cooled extrudate. The preferred particle size for instant release forms lies in the range of from 0.5 to 1.5 mm.
  • [0120]
    The particles, optionally together with conventional pharmaceutically acceptable excipients, may be further processed to conventional pharmaceutical dosage forms such as tablets, pastilles, suppositories, or be packed in capsules.
  • [0121]
    It is possible and particularly advantageous to produce pharmaceutical forms with rate-controlled release and improved dissolution rates of the active ingredients. This was not to be expected in view of the low solubility of the active ingredients in aqueous media.
  • EXAMPLES General Method
  • [0122]
    Powder mixes of the components were melt kneaded at 145 C. for 5 min. After cooling the solidified melts were ground and sieved. The sieve fraction 0.5-1.5 mm was used for the dissolution tests.
  • [0123]
    The composition of the individual powder mixes is listed in Table 1.
  • [0000]
    TABLE 1
    Example No. 1 2 3 4 5 6
    Active ingredient1) 30 30 30 30 30 40
    VP-VAC-copolymer2) 65 55 55 60 55 47.1
    Surfactant3) 5 15 5 5 4.3
    Citric acid 5
    HPMC 10 8.6
    Surfactant4) 15
    1)4-[[4-[2,4,6-trimethylphenyl)amino]-2-pyrimidinyl]amino]-benzonitrile
    2)Kollidon  VA64, VP/VAC = 60/40, BASF Aktiengesellschaft
    3)PEG-n-hydrogenated Castoroil
    4)polyoxyethylene polyoxypropylene blockcopolymer, mean mol. weight 4000 g/mol
  • [0124]
    The dissolution tests were carried out according to USP XXIII, paddle model, pH no change test, 0.1 M HCl, at 37 C., 100 rpm
  • [0125]
    The results are listed in Table 2.
  • [0000]
    TABLE 2
    Dissolution Rates of particles according to examples 1-6
    Dissolution [%] Dissolution [%]
    time Ex. 1 Ex. 2 Ex. 3 Ex. 4 time Ex. 5 Ex. 6
    [min] (IR) (IR) (IR) (IR) [min] (SR) (SR)
    5 53 65 58 57 1
    10 73 86 88 82 2
    15 77 91 95 89 3
    20 81 91 96 93 4
    30 87 94 99 94 6
    60 92 93 96 94 8 96 95
    120 93 94 97 95
    IR: Instant Release
    SR: Sustained Release
  • [0126]
    DSC-Measurements were performed with the formulations according to examples 1 to 6 in open pans (air) at temperatures of from 20→250 C., with a heating rate of 10 C. per minute. There is no indication of crystalline drug substance in the solid dispersions.
Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US4801460 *Apr 6, 1987Jan 31, 1989Basf AktiengesellschaftPreparation of solid pharmaceutical forms
US4917900 *Mar 25, 1988Apr 17, 1990Burroughs Wellcome Co.Controlled release formulations containing zidovudine
US5350741 *May 26, 1992Sep 27, 1994Kanji TakadaEnteric formulations of physiologically active peptides and proteins
US5456923 *Dec 23, 1993Oct 10, 1995Nippon Shinyaku Company, LimitedMethod of manufacturing solid dispersion
US5876760 *Jun 11, 1996Mar 2, 1999Ono Pharmaceutical Co., Ltd.Granules containing pranlukast, process for producing the granules, and method of improving adhesiveness of pranlukast
US5880130 *Dec 5, 1994Mar 9, 1999Zeneca Limited4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors
US6197779 *Mar 25, 1999Mar 6, 2001Janssen Pharmaceutica, Inc.HIV inhibiting pyrimidine derivative
US6878717 *Nov 1, 1999Apr 12, 2005Bart De CorteHIV replication inhibiting pyrimidines
US7037917 *Aug 5, 2003May 2, 2006Janssen Pharmaceutica, N.V.HIV replication inhibiting pyrimidines
US7734348 *May 10, 2005Jun 8, 2010Cardiac Pacemakers, Inc.System with left/right pulmonary artery electrodes
US7769450 *Nov 18, 2004Aug 3, 2010Cardiac Pacemakers, Inc.Cardiac rhythm management device with neural sensor
US7869881 *Dec 24, 2003Jan 11, 2011Cardiac Pacemakers, Inc.Baroreflex stimulator with integrated pressure sensor
US20050288278 *Aug 16, 2005Dec 29, 2005Bart De CorteHIV replication inhibiting pyrimidines
US20080176880 *Oct 31, 2007Jul 24, 2008Bart De CorteHiv replication inhibiting pyrimidines
US20080228238 *May 23, 2008Sep 18, 2008Cardiac Pacemakers, Inc.Automatic baroreflex modulation based on cardiac activity
US20100076511 *Nov 30, 2009Mar 25, 2010Heil Jr Ronald WBaroreflex stimulation system to reduce hypertension
US20100222832 *May 13, 2010Sep 2, 2010Yongxing ZhangMethods for using a pulmonary artery electrode
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7705148Feb 14, 2008Apr 27, 2010Janssen Pharmaceutica N.V.Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US7956063Jul 7, 2008Jun 7, 2011Janssen Pharmaceutica NvSalt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US8080551Jun 26, 2006Dec 20, 2011Janssen Pharmaceutica N.V.HIV inhibiting pyrimidines derivatives
US8101629Jul 28, 2010Jan 24, 2012Janssen Pharmaceutica N.V.Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US9580392Aug 5, 2014Feb 28, 2017Janssen Pharmaceutica NvHIV replication inhibiting pyrimidines
US20060252764 *Jun 26, 2006Nov 9, 2006Guillemont Jerome E GHIV inhibiting pyrimidines derivatives
US20080167464 *Feb 14, 2008Jul 10, 2008Didier Philippe Robert SchilsProcesses for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20090012108 *Jul 7, 2008Jan 8, 2009Jerome Emile GuillemontSalt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
US20110008434 *Jul 28, 2010Jan 13, 2011Guillemont Jerome Emile GeorgesSalt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
Classifications
U.S. Classification424/489
International ClassificationA61K9/14, C07D405/14, A61K47/38, A61P35/00, C07D239/50, C07D251/48, A61K9/16, A61P31/12, C07D239/47, C07D521/00, A61K47/34, A61P43/00, A61K31/496, A61K31/505, A61K31/53, A61K47/32, C07D251/18, C07D403/12, A61K47/12, C07D239/48
Cooperative ClassificationC07D251/18, C07D239/48, C07D405/14, A61K31/496, A61K9/1635, A61K31/53, C07D249/08, C07D403/12, A61K31/505, C07D239/50, C07D231/12, C07D233/56
European ClassificationA61K31/505, C07D249/08, C07D239/48, C07D231/12, C07D233/56, A61K31/496, A61K31/53, C07D239/50, C07D251/18, C07D405/14, C07D403/12
Legal Events
DateCodeEventDescription
Oct 2, 2014ASAssignment
Owner name: TIBOTEC PHARMACEUTICALS, IRELAND
Free format text: CHANGE OF NAME;ASSIGNOR:TIBOTEC PHARMACEUTICALS, LTD.;REEL/FRAME:033886/0623
Effective date: 20080814
Owner name: JANSSEN R&D IRELAND, IRELAND
Free format text: CHANGE OF NAME;ASSIGNOR:TIBOTEC PHARMACEUTICALS;REEL/FRAME:033871/0764
Effective date: 20120106